After a $134M IPO, Seres settles into a new R&D shop

Seres Therapeutics ($MCRB), one of the year's IPO success stories, has leased an 83,000-square-foot R&D outpost in its native Cambridge, MA, pressing forward with a pipeline of microbiome treatments. As the Boston Business Journal reports, Seres has signed up to become the final tenant in a BioMed Realty-owned building that is also home to AbbVie ($ABBV), CRISPR Therapeutics, Synlogic and RaNA Therapeutics. Seres is in Phase II with SER-109, a Tylenol-sized capsule designed to treat recurrent Clostridium difficile infections by changing patients' bacterial makeup. Story

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.